An Open-Label Study to Evaluate the Effect of the Administration of FX006 on Synovial Inflammation in Patients With Osteoarthritis of the Knee
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs Triamcinolone (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Flexion Therapeutics
- 08 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 28 Feb 2019 According to Flexion Therapeutics media release, topline results are anticipated in 2020.
- 18 Jan 2019 Planned End Date changed from 1 Nov 2019 to 1 Jun 2020.